At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 12, 2026 at 09:40 ET
Kura Oncology announced that updated Phase 1 KOMET-007 data for ziftomenib in frontline AML will be presented at EHA 2026. The 99-patient dataset shows high CRc rates (90-96%) and deep MRD negativity (>80%) across NPM1-m and KMT2A-r subtypes, with median duration of CRc not reached in NPM1-m patients at ~15 months follow-up. The Phase 3 KOMET-017 trial is enrolling, with potential for accelerated FDA review in 2028.
- Oral presentation at EHA 2026 on June 14 will feature 99-patient dataset with extended follow-up
- CRc rates: 96% (NPM1-m) and 90% (KMT2A-r) in frontline AML
- MRD-negativity rates: 83% (NPM1-m) and 82% (KMT2A-r) among CRc responders
- Median duration of CRc not reached in NPM1-m at 14.9 months median follow-up
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access